רווחיות מכירות לפי רווח נקי bluebird bio Inc. (BLUE)

bluebird bio, Inc. (BLUE) is a pioneer in treating rare blood pathologies using unique lentiviral technologies. The business is based on creating gene therapies from modified patient cells. The integral net margin indicator demonstrates current profitability, where the value -192.40 reflects the metric's balance. However, high product implementation costs and operational complexities create risks in the competitive struggle for market share.
פילוחים אנליטיים ודוחות נתונים של חברת bluebird bio, Inc. (BLUE)

bluebird bio, Inc. (BLUE) focuses on developing innovative one-time gene therapies to treat severe hereditary blood disorders. Mathematically, this process is reflected through the ratio of net income to total revenue. This metric measures the efficiency of converting revenue into final capital after deducting all operating and tax expenses. By analyzing the net profit margin of trading and production activities, an investor assesses the business's resilience to inflation. The trend in the net profit margin of trading and production activities reveals the balance between costly research and development and the market value of patient cures.